The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Expert Opinion on Drug Metabolism & Toxicology

• Publication date

  2013-09-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/17425255.2013.811489PMID 23795716
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Magnetic resonance imaging characterization of different experimental autoimmune encephalomyelitis models and the therapeutic effect of glatiramer acetate.

  2013cited by this paper
• Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosis

  2013cited by this paper
• The mechanism of action of glatiramer acetate in multiple sclerosis and beyond.

  2013cited by this paper
• Randomized study combining interferon and glatiramer acetate in multiple sclerosis

  2013cited by this paper
• Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

  2012influential reference
• Glatiramer Acetate Increases Phagocytic Activity of Human Monocytes In Vitro and in Multiple Sclerosis Patients

  2012cited by this paper
• Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

  2012cited by this paper
• Glatiramer acetate for treatment of relapsing–remitting multiple sclerosis

  2012cited by this paper
• Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

  2012cited by this paper
• Natalizumab-associated progressive multifocal leukoencephalopathy.

  2012cited by this paper
• Safety, Pharmacokinetic, and Pharmacodynamic Evaluations of PI‐2301, a Potent Immunomodulator, in a First‐in‐Human, Single‐Ascending‐Dose Study in Healthy Volunteers

  2011cited by this paper
• Interferon therapy in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of the comparative trials.

  2011cited by this paper
• Glatiramer acetate (GA, Copolymer-1) an hypothetical treatment option for Rett syndrome.

  2011cited by this paper
• Glatiramer Acetate Modulates TNF-α and IL-10 Secretion in Microglia and Promotes Their Phagocytic Activity

  2011cited by this paper
• Recent insights into the mechanism of action of glatiramer acetate.

  2011cited by this paper
• Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

  2011cited by this paper
• Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study

  2011cited by this paper
• A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis

  2011cited by this paper
• The Global Adherence Project (GAP): a multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis

  2011cited by this paper
• Augmentation of regulatory B cell activity in experimental allergic encephalomyelitis by glatiramer acetate.

  2011cited by this paper
• A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

  2010cited by this paper
• B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis.

  2010cited by this paper
• Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.

  2010cited by this paper
• Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response.

  2010cited by this paper
• Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE.

  2010influential reference
• Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis

  2010cited by this paper
• Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update

  2010cited by this paper
• Vitamin D and multiple sclerosis.

  2010cited by this paper
• Glatiramer Acetate

  2010cited by this paper
• Efficacy of treatment of MS with IFN -1b or glatiramer acetate by monthly brain MRI in the BECOME study

  2009cited by this paper
• The glatiramoid class of immunomodulator drugs

  2009cited by this paper
• 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

  2009cited by this paper
• Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.

  2009influential reference
• An overview of gene-epigenetic-environmental contributions to MS causation.

  2009cited by this paper
• Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.

  2008cited by this paper
• Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis?

  2008cited by this paper
• Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid

  2008cited by this paper
• Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-β 1a, and high doses of immunoglobulins

  2007cited by this paper
• Multiple Sclerosis

  2007cited by this paper
• CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

  2007cited by this paper
• Environmental risk factors for multiple sclerosis. Part I: The role of infection

  2007cited by this paper
• Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial

  2007cited by this paper
• Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors

  2007cited by this paper
• The therapeutic effect of glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-inflammatory T-cells.

  2007cited by this paper
• The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration.

  2006cited by this paper
• Therapeutic Induction of Regulatory, Cytotoxic CD8+ T Cells in Multiple Sclerosis1

  2006cited by this paper
• During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4.

  2006cited by this paper
• A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

  2006cited by this paper
• Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study.

  2006cited by this paper
• A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients

  2006cited by this paper
• Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis.

  2006cited by this paper
• Combined treatment of glatiramer acetate and low doses of immunosuppressive drugs is effective in the prevention of graft rejection.

  2005cited by this paper
• The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice.

  2005cited by this paper
• Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate.

  2005cited by this paper
• Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3.

  2005cited by this paper
• Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease.

  2004cited by this paper
• Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate.

  2004cited by this paper
• Glatiramer Acetate (Copolymer-1, Copaxone) Promotes Th2 Cell Development and Increased IL-10 Production Through Modulation of Dendritic Cells1

  2003cited by this paper
• Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy

  2003cited by this paper
• Therapeutic vaccine for acute and chronic motor neuron diseases: Implications for amyotrophic lateral sclerosis

  2003cited by this paper
• Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ

  2003cited by this paper
• Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor.

  2003cited by this paper
• The Natural Killer Cell – Friend or Foe in Autoimmune Disease?

  2002cited by this paper
• Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: a mechanism for therapeutic efficacy in multiple sclerosis

  2002cited by this paper
• Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor.

  2002cited by this paper
• Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS.

  2002cited by this paper
• Copaxone’s effect on MRI-monitored disease in relapsing MS is reproducible and sustained

  2002cited by this paper
• Oral treatment of mice with copolymer 1 (glatiramer acetate) results in the accumulation of specific Th2 cells in the central nervous system.

  2002influential reference
• Risk-Benefit Assessment of Glatiramer Acetate in Multiple Sclerosis

  2001influential reference
• Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article].

  2001cited by this paper
• European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis

  2001cited by this paper
• Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: Implications for glaucoma

  2001cited by this paper
• Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone.

  2001cited by this paper
• T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies.

  2000cited by this paper
• Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis

  2000cited by this paper
• Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1.

  2000cited by this paper
• Mechanisms of immunomodulation by glatiramer acetate

  2000cited by this paper
• Multiple sclerosis.

  2000cited by this paper
• Glatiramer acetate (Copaxone) treatment in relapsing–remitting MS

  2000cited by this paper
• Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.

  2000cited by this paper
• Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking.

  1999cited by this paper
• Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

  1998cited by this paper
• Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1.

  1998cited by this paper
• Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis.

  1997cited by this paper
• Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses.

  1996cited by this paper
• Copolymer 1

  1995cited by this paper
• Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

  1995cited by this paper
• Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.

  1995cited by this paper
• Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity.

  1994influential reference
• A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis.

  1987cited by this paper
• Surface markers and cytotoxic activity of blood natural killer cells studied at the single cell level in Hodgkin's disease.

  1985cited by this paper
• Clinical Trials of Copolymer I in Multiple Sclerosis

  1984cited by this paper
• Multiple sclerosis: Trial of a synthetic polypeptide

  1982cited by this paper
• Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factor.

  1980cited by this paper
• Effect of a synthetic polypeptide (Cop 1) on patients with multiple sclerosis and with acute disseminated encephalomyelitis

  1977cited by this paper
• Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomeylitis. Preliminary report.

  1977cited by this paper
• Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/1352458509358088

  year unknowncited by this paper

• GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial

  2026cites this paper
• Citrullinated peptides as drug candidates for rheumatoid arthritis

  2025cites this paper
• Exploring drug interactions between newer antidepressants and medications used to treat neurological disorders

  2025cites this paper
• Antimicrobial peptide glatiramer acetate targets Pseudomonas aeruginosa lipopolysaccharides to breach membranes without altering lipopolysaccharide modification

  2023cites this paper
• The Role of the Intestinal Microbiome in Multiple Sclerosis—Lessons to Be Learned from Hippocrates

  2023cites this paper
• Pregnancy, Fetal, and Infant Outcomes Following Maternal Exposure to Glatiramer Acetate During Pregnancy and Breastfeeding

  2022cites this paper
• Induction of a higher-ordered architecture in glatiramer acetate improves its biological efficiency in an animal model of multiple sclerosis.

  2020cites this paper
• The influence of glatiramer acetate on Th17-immune response in multiple sclerosis

  2020cites this paper
• Safety of potential breast milk exposure to IFN-β or glatiramer acetate

  2020cites this paper
• Glatiramer acetate persists at the injection site and draining lymph nodes via electrostatically‐induced aggregation

  2019cites this paper
• Lymphopenia and DMTs for relapsing forms of MS

  2019cites this paper
• Effects of Fasting on Multiple Sclerosis

  2018cites this paper
• Practical Evidence-Based Recommendations for Patients with Multiple Sclerosis Who Want to Have Children

  2018cites this paper
• Update on disease-modifying therapies for multiple sclerosis

  2017cites this paper
• Pharmacogenetics of Neurodegenerative Disorders

  2017cites this paper
• Fasting and neurologic diseases

  2016cites this paper
• miRNAs Participate in MS Pathological Processes and Its Therapeutic Response

  2016cites this paper
• The heritage of glatiramer acetate and its use in multiple sclerosis

  2016cites this paper
• Preventive and Predictive Genetics: Towards Personalised Medicine

  2015influential citation
• Modern analytics for synthetically derived complex drug substances: NMR, AFFF–MALS, and MS tests for glatiramer acetate

  2015cites this paper
• Glatiramer Acetate 40 mg/mL in Relapsing–Remitting Multiple Sclerosis: A Review

  2015cites this paper
• Is it safe for Multiple Sclerosis patients to fast

  2015cites this paper
• New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.

  2015cites this paper
• Expression, Regulation and Function of MicroRNAs in Multiple Sclerosis

  2014cites this paper
• Islamic fasting and multiple sclerosis

  2014cites this paper
• Central Lancashire Online Knowledge (CLoK)

  year unknowncites this paper